CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 101–200 of 1,725
Gautam, M., Jozic, A., Su, G. L.-N., Herrera-Barrera, M., Curtis, A., Arrizabalaga, S., Tschetter, W., Ryals, R. C., & Sahay, G. (2023) · Nature Communications · doi:10.1038/s41467-023-42189-3 · Cited by 123
Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
Belgrad, J., Fakih, H. H., & Khvorova, A. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0068 · Cited by 142
“One new modality that we can follow is the use of CRISPR-Cas9 for the treatment of hereditary angioedema and transthyretin amyloidosis by Intellia Therapeutics [94,95].”
Nakamura, T., Sato, Y., Yamada, Y., Abd Elwakil, M. M., Kimura, S., Younis, M. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114417 · Cited by 121
RNA therapeutics: updates and future potential
Zhang, C., & Zhang, B. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2171-2 · Cited by 130
“The preclinical studies and first-in-human interim clinical data analysis show decreased concentration of serum TTR in both animal models and patients with hereditary ATTR, demonstrating durable targeted knockout of TTR (Gillmore et al., 2021).”
BackgroundViral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets
Taghdiri, M., & Mussolino, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137333 · Cited by 145
“More recently, a complementary study successfully achieved a significant decrease in TTR protein serum levels in six patients upon LNP delivery of CRISPR-Cas9 to genetically inactivate the TTR gene [116].”
BackgroundJiang, L., Lin, J., Zhao, S., Wu, J., Jin, Y., Li, Y., Wu, N., Wu, Z., Wang, Y., & Lin, M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.703110 · Cited by 139
“The robustness of subcutaneous, intravitreal, and intrathecal delivery in hereditary transthyretin amyloidosis, cytomegalovirus retinitis, and spinal muscular atrophy treatment has provided perfect examples for a safe and efficient delivery of the therapeutic construct (Group, 2002; Aartsma-Rus, 2017; Wood, 2018; Gill…”
BackgroundRecent advances in biomimetic nanodelivery systems: New brain-targeting strategies
Liao, J., Fan, L., Li, Y., Xu, Q.-Q., Xiong, L., Zhang, S., Liu, J.-H., Xiao, Z.-C., Zhang, C., Yang, J., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.05.009 · Cited by 125
Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice
Lopes, L. R., Ho, C. Y., & Elliot, P. M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae421 · Cited by 143
“…genetic defect in cardiomyopathies, including gene repair mechanisms via CRISPR/cas9, splicing correction, gene replacement, and RNA interfering methods leading to gene silencing 73,74 ( Figure 1 75 Both efficiency and safety are major challenges for translation of these therapies into humans.”
BackgroundA new age of precision gene therapy
Schambach, A., Buchholz, C. J., Torres-Ruiz, R., Cichutek, K., Morgan, M. A., Trapani, I., & Büning, H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01952-9 · Cited by 145
Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids
Prakash, G., Shokr, A., Willemen, N. G. A., Bashir, S. M., Shin, S. R., & Hassan, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114197 · Cited by 126
Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis
Carroll, A. S., Dyck, P. J. B., de Carvalho, M. A., Kennerson, M. L., Reilly, M. M., Kiernan, M. C., & Vucic, S. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327909 · Cited by 131
Xue, L., Zhao, G., Gong, N., Han, X., Shepherd, S. J., Xiong, X., Xiao, Z., Palanki, R., Xu, J., Swingle, K. L., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01747-6 · Cited by 150
“In clinical trials, LNPs encapsulating Cas9 mRNA and single guide RNA (sgRNA) targeting transthyretin ( TTR ) have demonstrated durable knockout of TTR to treat hereditary transthyre-tin amyloidosis 12,13 .”
World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Brito, D. A., Albrecht, F. C., de Arenaza, D. P., Bart, N., Better, N., Carvajal-Juárez, I., Conceição, I. M., Damy, T., Dorbala, S., Fidalgo, J.-C., et al. (2023) · Global Heart · doi:10.5334/gh.1262 · Cited by 139
Self-citationAdvances in mRNA non-viral delivery approaches
Ibba, M. L., Ciccone, G., Esposito, C. L., Catuogno, S., & Giangrande, P. H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113930 · Cited by 112
Recent advances in nanoparticulate RNA delivery systems
Witten, J. J., Hu, Y., Langer, R., & Anderson, D. G. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307798120 · Cited by 121
Programmable gene insertion in human cells with a laboratory-evolved CRISPR-associated transposase
Witte, I. P., Lampe, G. D., Eitzinger, S., Miller, S. M., Berríos, K. N., McElroy, A. N., King, R. T., Stringham, O. G., Gelsinger, D. R., Vo, P. L. H., et al. (2025) · Science · doi:10.1126/science.adt5199 · Cited by 125
“These genome editing technologies have been effectively deployed in the clinic as one-time treatments for a variety of genetic disorders (13–16), with more than 60 clinical trials underway (17).”
CRISPR-based therapeutics: current challenges and future applications
Modell, A. E., Lim, D., Nguyen, T. M., Sreekanth, V., & Choudhary, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.10.012 · Cited by 104
Current landscape of mRNA technologies and delivery systems for new modality therapeutics
Lu, R., Hsu, H.-E., Perez, S. J. L. P., Kumari, M., Chen, G., Hong, M.-H., Lin, Y.-S., Liu, C.-H., Ko, S.-H., Concio, C. A. P., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01080-z · Cited by 129
“Additionally, CRISPR-Cas9 is being evaluated for in vivo delivery using mRNA-LNP system, with treating transthyretin amyloidosis initiated in 2021 [27].”
Carrier strategies boost the application of CRISPR/Cas system in gene therapy
Xu, Z., Wang, Q., Zhong, H., Jiang, Y., Shi, X., Yuan, B., Yu, N., Zhang, S., Yuan, X., Guo, S., et al. (2022) · Exploration · doi:10.1002/exp.20210081 · Cited by 109
Dobrowolski, C. N., Paunovska, K., Echeverri, E. S., Loughrey, D., Sanchez, A. J. D. S., Ni, H., Hatit, M. Z. C., Lokugamage, M. P., Kuzminich, Y., Peck, H. E., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01146-9 · Cited by 117
“Finally, to control for the possibility that the differential stability of PEG lipids could lead to bias in the pooled screening system, we injected three groups of mice: (1) one group of mice received an LNP with C14 PEG, then later an LNP with C18 PEG, (2) one group received an LNP with C18 PEG, then later an LNP wi…”
CRISPR engineering in organoids for gene repair and disease modelling
Geurts, M. H., & Clevers, H. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00013-5 · Cited by 103
Garus, A., & Autexier, C. (2021) · RNA · doi:10.1261/rna.078953.121 · Cited by 111
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics
Kang, D. D., Li, H., & Dong, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114961 · Cited by 100
Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol
Johansson, J. M., Rietz, H. D., Hedlund, H., Eriksson, H. C., Blenke, E. O., Pote, A. R., Harun, S., Nordenfelt, P., Lindfors, L., & Wittrup, A. (2025) · Nature Communications · doi:10.1038/s41467-025-60959-z · Cited by 142
“While cytosolic delivery using non-particulate formulations has proven feasible for relatively small antisense and siRNA molecules, larger molecules such as mRNAs or CRISPR-based compounds 6,7 currently require formulation in lipid nanoparticles (LNPs) for functional delivery.”
Comprehensive assessment of miniature CRISPR-Cas12f nucleases for gene disruption
Xin, C., Yin, J., Yuan, S., Ou, L., Liu, M., Zhang, W., & Hu, J. (2022) · Nature Communications · doi:10.1038/s41467-022-33346-1 · Cited by 110
Tremblay, F., Xiong, Q., Shah, S. S., Ko, C., Kelly, K., Morrison, M. S., Giancarlo, C., Ramírez, R. N., Hildebrand, E. M., Voytek, S. B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03508-x · Cited by 125
“…gene editing and base editing approaches for therapeutic target inhibition have been demonstrated in preclinical species 14–19 and in humans 20–22 , the ability to reverse these changes in the DNA sequence in vivo has not been published and would require identification of a new DNA-targeting…”
An engineered hypercompact CRISPR-Cas12f system with boosted gene-editing activity
Wu, T., Liu, C., Zou, S., Lyu, R., Yang, B., Yan, H., Zhao, M., & Tang, W. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01380-9 · Cited by 109
Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids
Bader, J., Brigger, F., & Leroux, J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115461 · Cited by 114
Park, S. H., Cao, M., Pan, Y., Davis, T. H., Saxena, L., Deshmukh, H., Fu, Y., Treangen, T., Sheehan, V. A., & Bao, G. (2022) · Science Advances · doi:10.1126/sciadv.abo7676 · Cited by 93
“Although PCR-based target sequence enrichment and long-read sequencing have been used to analyze CRISPR-Cas9–induced LDs ( 12 , 16 , 21 ), these approaches are limited by artifacts and PCR biases in multitemplate long-range PCR (L-R PCR) because of the high complexity of gene-edited alleles.”
Focusing on mitochondria in the brain: from biology to therapeutics
Song, N., Mei, S., Wang, X.-X., Hu, G., & Lu, M. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00409-w · Cited by 119
“Particularly, the beneficial efficacy of the CRISPR system in clinical practice has opened a new era in treating rare genetic diseases [437], and also shed light on the attempts to edit mitochondrial genome for treating mitochondrial diseases (Fig.”
BackgroundSignaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 113
“Recently, the results of a phase 1 clinical trial aiming to treat hereditary transthyretin amyloidosis by in vivo gene editing were published.(517) Hereditary transthyretin amyloidosis is a rare disease and is estimated to occur in approximately 50,000 individuals worldwide.”
BackgroundDong, W. X., Li, Z., Hou, T., Shen, Y., Guo, Z., Su, Y., Chen, Z., Pan, H., Jiang, W., & Wang, Y. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c00451 · Cited by 98
Han, X., Alameh, M., Gong, N., Xue, L., Ghattas, M., Bojja, G., Xu, J., Zhao, G., Warzecha, C. C., Padilla, M. S., et al. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01557-2 · Cited by 112
“G211) was chemically synthesized by AxoLabs (Supplementary Table 4) 43 .”
Self-citationHołubowicz, R., Du, S. W., Felgner, J. H., Šmidák, R., Choi, E. H., Palczewska, G., Menezes, C. R., Dong, Z., Gao, F., Medani, O., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01296-2 · Cited by 118
“…achieving this transient action have been proposed, such as by virus-like particle (VLP) delivery 28,32,33 , mRNA lipid-nanoparticle (LNP) delivery 34 and by direct ribonucleoprotein (RNP) delivery, either as naked RNP or as a lipoplex with cationic lipid reagents such as Lipofectamine 2000 35–38…”
Optimizing 5’UTRs for mRNA-delivered gene editing using deep learning
Castillo-Hair, S., Fedak, S., Wang, B., Linder, J., Havens, K., Certo, M., & Seelig, G. (2024) · Nature Communications · doi:10.1038/s41467-024-49508-2 · Cited by 98
Lipid nanoparticles: Composition, formulation, and application
Xu, S., Hu, Z., Song, F., Xu, Y. G., & Han, X. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101463 · Cited by 126
“158 NTLA-2001 is now in phase 3 clinical trial (NCT06672237 and NCT06128629).”
Self-citationJohansson, Å., Andreassen, O. A., Brunak, S., Franks, P. W., Hedman, H., Loos, R. J. F., Meder, B., Melén, E., Wheelock, C. E., & Jacobsson, B. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13640 · Cited by 127
“The latest success comes from a first-in-human clinical trial using CRISPR-Cas9 in hereditary amyloidosis [36].”
Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy
Poli, L., Labella, B., Piccinelli, S. C., Caria, F., Risi, B., Damioli, S., Padovani, A., & Filosto, M. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1242815 · Cited by 118
Gene therapy for CNS disorders: modalities, delivery and translational challenges
Gao, J., Gunasekar, S., Xia, Z. J., Shalin, K., Jiang, C., Chen, H., Lee, D., Lee, S., Pisal, N. D., Luo, J. N., et al. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00829-7 · Cited by 102
“CRISPR–Cas9 systems have been harnessed for various preclinical and clinical applications, and several clinical trials are underway for CNS disorders 37–40 (see Supplementary Table 1).”
Evolution of nanomedicine formulations for targeted delivery and controlled release
Puri, S., Mazza, M., Roy, G., England, R., Zhou, L., Nourian, S., & Subramony, J. A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114962 · Cited by 104
Li, X., Qi, J., Wang, J., Hu, W., Zhou, W., Wang, Y., & Li, T. (2024) · Theranostics · doi:10.7150/thno.84291 · Cited by 110
“NTLA-2001 aims to edit TTR in hepatocytes, leading to a decrease in the production of both wild-type and mutant TTR after a single administration [149].”
BackgroundThe Last Decade in Cardiac Amyloidosis
Fontana, M., Ioannou, A., Cuddy, S. A. M., Dorbala, S., Masri, A., Moon, J., Singh, V., Clerc, O. F., Hanna, M. A., Ruberg, F. L., et al. (2025) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.10.011 · Cited by 106
Self-citationOff-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges
Kalter, N., Fuster‐García, C., Silva, A., Ronco-Díaz, V., Roncelli, S., Turchiano, G., Gorodkin, J., Cathomen, T., Benabdellah, K., Lee, C. M., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102636 · Cited by 134
“20,213,214 Never-theless, caution should be taken when interpreting the absence of detectable OTA, as it may reflect limitations in assay sensitivity or the selection of inappropriate detection methods rather than an actual absence of OT effects.”
John, R., monpara, J., Swaminathan, S., & Kalhapure, R. S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010131 · Cited by 107
“This therapeutic CRISPR-Cas9 system identified seven potential target sites [140].”
Soroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.023 · Cited by 102
Gene therapy clinical trials worldwide to 2023—an update
Ginn, S. L., Mandwie, M., Alexander, I. E., Edelstein, M. L., & Abedi, M. R. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3721 · Cited by 112
“82 Transient gene delivery systems can be desirable to reduce the off-target effect and improve the safety of genome editing.”
Fei, Y., Yu, X., Liu, P., Ren, H., Wei, T., & Cheng, Q. (2024) · Advanced Materials · doi:10.1002/adma.202409812 · Cited by 104
Ling, S., Zhang, X., Dai, Y., Jiang, Z., Zhou, X., Lu, S., Qian, X., Liu, J., Selfjord, N., Şatır, T. M., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-024-01851-7 · Cited by 108
“Other research teams and ours have begun clinical trials of in vivo CRISPR delivery to treat inherited ocular and liver diseases and virus infection by using adeno-associated virus (AAV), lipid nanoparticles (LNPs) and virus-like particles (VLPs) as the delivery tool, respectively 1–3 .”
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis
Ioannou, A., Fontana, M., & Gillmore, J. D. (2023) · BioDrugs · doi:10.1007/s40259-023-00577-7 · Cited by 101
“The risk of off-target editing with NTLA-2001 is therefore deemed to be low; however, patients who receive this geneediting therapy will require long-term follow-up [25].”
BackgroundInfluentialSelf-citationFrameworks for transformational breakthroughs in RNA-based medicines
Androsavich, J. R. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00943-2 · Cited by 108
“Commonly reported drug-related adverse events include infusion or injection site reactions, fatigue, headache, nausea and chills 45,100,118,119 .”
InfluentialEmerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
Bian, X., Zhou, L., Luo, Z., Liu, G., Hang, Z., Li, H., Li, F., & Wen, Y. (2025) · ACS Nano · doi:10.1021/acsnano.4c11858 · Cited by 110
Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy
Dubey, A. K., & Mostafavi, E. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1259435 · Cited by 103
Current and future direction in treatment of HPV-related cervical disease
Khairkhah, N., Bolhassani, A., & Najafipour, R. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02199-y · Cited by 98
“Less amount of mutated TTR proteins decrease the chance of formation and accumulation amyloidosis [164].”
BackgroundRecent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing
Sinclair, F., Begum, A. A., Dai, C. C., Tóth, I., & Moyle, P. M. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01320-z · Cited by 104
“Intravenous administration of NTLA-2001 composed of lipid nanoparticle encapsulating messenger RNA for Cas9 protein and a single guide RNA targeting T transthyretin (TTR) resulted in knocking out of TTR protein and thus led to decreased concentration (> 50% depending on dose concentration) of TTR protein in serum with…”
BackgroundLopes, R., & Prasad, M. K. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1339189 · Cited by 82
Hashiba, K., Taguchi, M., Sakamoto, S., Otsu, A., Maeda, Y., Ebe, H., Arimichi, O., Harashima, H., & Sato, Y. (2024) · Communications Biology · doi:10.1038/s42003-024-06235-0 · Cited by 98
Rational design of anti‐inflammatory lipid nanoparticles for mRNA delivery
Zhang, H., Han, X., Alameh, M., Shepherd, S. J., Padilla, M. S., Xue, L., Butowska, K., Weissman, D., & Mitchell, M. J. (2022) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37356 · Cited by 88
“Therefore, premedication with anti-inflammatory drugs and antihistamines is needed for LNP-based mRNA therapeutics in the clinic.(22) Hence, there is an urgent need to develop LNP formulations that can suppress unwanted innate immune responses to not only improve the safety of LNPs but also enhance”
BackgroundCationic cholesterol-dependent LNP delivery to lung stem cells, the liver, and heart
Radmand, A., Kim, H., Beyersdorf, J. P., Dobrowolski, C. N., Zenhausern, R., Paunovska, K., Huayamares, S. G., Hua, X., Han, K., Loughrey, D., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307801120 · Cited by 88
Lipid-based nanosystems: the next generation of cancer immune therapy
Cheng, Z., Fobian, S., Gurrieri, E., Amin, M., D’Agostino, V., Falahati, M., Zalba, S., Debets, R., Garrido, M. J., Saeed, M., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01574-1 · Cited by 106
“Lastly, LNPs have recently been employed for the first time to enable gene editing in the clinic [186].”
MethodLipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics
Semple, S. C., Leone, R. D., Barbosa, C., Tam, Y. K., & Lin, P. J. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020398 · Cited by 90
Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma
Kong, H., Ju, E., Yi, K., Xu, W., Lao, Y., Cheng, D., Zhang, Q., Tao, Y., Li, M., & Ding, J. (2021) · Advanced Science · doi:10.1002/advs.202102051 · Cited by 85
Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease
Palanki, R., Bose, S. K., Dave, A., White, B. M., Berkowitz, C., Luks, V., Yaqoob, F., Han, E., Swingle, K. L., Menon, P., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c02268 · Cited by 77
Engineering approaches for RNA-based and cell-based osteoarthritis therapies
DeJulius, C. R., Walton, B. L., Colazo, J. M., d’Arcy, R., Francini, N., Brunger, J. M., & Duvall, C. L. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01067-4 · Cited by 92
“115), transthyretin amyloidosis 116 , transfusion-dependent β-thalassaemia 117 and sickle cell disease 117 , and for the engineering of chimeric antigen receptor (CAR) T cells 118 .”
Targeted nonviral delivery of genome editors in vivo
Tsuchida, C. A., Wasko, K. M., Hamilton, J. R., & Doudna, J. A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307796121 · Cited by 90
“Upon passive targeting of the liver, editing of the TTR gene resulted in no detectable off - target editing or severe adverse events, but significant reduction of path - ogenic misfolded transthyretin (129, 130).”
BackgroundHan, X., Xu, J., Xu, Y., Alameh, M., Xue, L., Gong, N., El-Mayta, R. D., Palanki, R., Warzecha, C. C., Zhao, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45537-z · Cited by 99
“Given the growing interest in CRISPR/Cas9-mediated liver gene editing as exempli fi ed by Intellia ’ s LNP-mediated transthyretin ( TTR ) knockout 38 , we chose TTR as a model target and co-delivered Cas9 mRNA and TTR sgRNA.”
MethodSelf-citationGene therapy for liver diseases — progress and challenges
Zabaleta, N., Unzu, C., Weber, N. D., & González‐Aseguinolaza, G. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00729-0 · Cited by 80
Sago, C. D., Lokugamage, M. P., Loughrey, D., Lindsay, K. E., Hincapie, R., Krupczak, B. R., Kalathoor, S., Sato, M., Echeverri, E. S., Fitzgerald, J. P., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00847-9 · Cited by 76
“Finally, given that iOligos interfere with a complex and dynamic process inside the cell (as the mRNA is translated into protein and then interacts with the sgRNA), we think that future studies titrating (1) the ratios of Cas9 mRNA, sgRNA and iOligos, H ep at oc yt es , i nd el s (% )”
BackgroundMethodLi, Z., Zhang, X., Ho, W., Li, F., Gao, M., Bai, X., & Xu, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c07822 · Cited by 79
Walther, J., Porenta, D., Wilbie, D., Seinen, C. W., Benne, N., Yang, Q., de Jong, O. G., Lei, Z., & Mastrobattista, E. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114207 · Cited by 84
Meijboom, K. E., Abdallah, A., Fordham, N. P., Nagase, H., Rodríguez, T., Kraus, C., Gendron, T. F., Krishnan, G., Esanov, R., Andrade, N. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33332-7 · Cited by 85
Sanchez, A. J. D. S., Loughrey, D., Echeverri, E. S., Huayamares, S. G., Radmand, A., Paunovska, K., Hatit, M. Z. C., Tiegreen, K. E., Santangelo, P. J., & Dahlman, J. E. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304033 · Cited by 90
Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies
Huang, X., Ma, Y., Ma, G., & Xia, Y. (2024) · Research · doi:10.34133/research.0370 · Cited by 96
“…clinical trials are presently investigating the utilization of LNP for mRNA therapeutics in various conditions, including the first in vivo application of CRISPR/Cas9 treatment administered intravenously for the management of patients with transthyretin amyloidosis (ATTR amyloidosis) [27].”
BackgroundInfluentialAdvances in CRISPR-Cas technology and its applications: revolutionising precision medicine
Azeez, S. S., Hamad, R. S., Hamad, B., Shekha, M. S., & Bergsten, P. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1509924 · Cited by 107
Cas13d: A New Molecular Scissor for Transcriptome Engineering
Gupta, R. K., Ghosh, A., Chakravarti, R., Singh, R., Ravichandiran, V., Swarnakar, S., & Ghosh, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.866800 · Cited by 81
Ding, L., Wu, Y., Liu, L.-E., He, L.-L., Yu, S.-C., Effah, C., Liu, X., Qu, L., & Wu, Y.-J. (2022) · Biosensors & bioelectronics · doi:10.1016/j.bios.2022.114827 · Cited by 63
Paunovska, K., Sanchez, A. J. D. S., Lokugamage, M. P., Loughrey, D., Echeverri, E. S., Cristian, A., Hatit, M. Z. C., Santangelo, P. J., Zhao, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c03741 · Cited by 80
Nucleic acid therapeutics: Past, present, and future
Naeem, S., Zhang, J., Zhang, Y., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102440 · Cited by 91
LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea
Mohanna, S. Z. M., Djaksigulova, D., Hill, A. M., Wagner, P. K., Simpson, E. M., & Leavitt, B. R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.042 · Cited by 79
Nanoparticle stereochemistry-dependent endocytic processing improves in vivo mRNA delivery
Hatit, M. Z. C., Dobrowolski, C. N., Lokugamage, M. P., Loughrey, D., Ni, H., Zurla, C., Sanchez, A. J. D. S., Radmand, A., Huayamares, S. G., Zenhausern, R., et al. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01138-9 · Cited by 76
Immunological barriers to haematopoietic stem cell gene therapy
Charlesworth, C. T., Hsu, I., Wilkinson, A. C., & Nakauchi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00698-0 · Cited by 74
The Transcriptional Response to Lung-Targeting Lipid Nanoparticles in Vivo
Radmand, A., Lokugamage, M. P., Kim, H., Dobrowolski, C. N., Zenhausern, R., Loughrey, D., Huayamares, S. G., Hatit, M. Z. C., Ni, H., Cid, A. D., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04479 · Cited by 79
Gene editing therapeutics based on mRNA delivery
Popovitz, J., Sharma, R. K., Hoshyar, R., Kim, B. S., Murthy, N., & Lee, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115026 · Cited by 81
Gene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 77
“More importantly, they demonstrated that a single dose of NTLA-200 was able to reduce transthyretin by 87% on average, which lasted for over a year without relapse (NCT04601051) (Gillmore et al., 2021).”
BackgroundAdams, D. H., Sekijima, Y., Conceição, I., Waddington-Cruz, M., Polydefkis, M., Echaniz-Laguna, A., & Reilly, M. M. (2023) · Lancet Neurology · doi:10.1016/s1474-4422(23)00334-4 · Cited by 55
Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application
Mashima, R., & Takada, S. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100341 · Cited by 78
“NCT04601051 Amyloidosis hATTR Transthyretin Cas9 mRNA Phase 1 Recruiting Intellia Therapeutics [61]”
BackgroundLipid nanoparticles: The game-changer in CRISPR-Cas9 genome editing
Farsani, A. M., Mokhtari, N., Nooraei, S., Bahrulolum, H., Akbari, A., Farsani, Z. M., Khatami, S., Ebadi, M. S., & Ahmadian, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24606 · Cited by 98
“Additionally, five out of the six patients exhibited elevated d-dimer values between 4 and 24 h after injection, but these values returned to normal in all cases by day 7 [108].”
BackgroundCavazza, A., Molina-Estévez, F. J., Reyes, Á. P., Ronco-Díaz, V., Naseem, A., Malenšek, Š., Pečan, P., Santini, A., Heredia, P., Aguilar-González, A., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102457 · Cited by 80
“98 Inactivation of kalikrein K1 ( KLKB1 gene), part of the NTLA-2002 phase I/II clinical trial, is seeking therapeutic solution for patients suffering from hereditary angioedema.”
The use of new CRISPR tools in cardiovascular research and medicine
Nishiga, M., Liu, C., Qi, L. S., & Wu, J. C. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00669-3 · Cited by 73
Li, Z., Wang, J., Xu, J.-P., Wang, J., & Yang, X. F. (2023) · Military Medical Research · doi:10.1186/s40779-023-00447-x · Cited by 93
“The most efficient method of in vivo delivery of editors reported so far is the use of AAV, which can deliver editor-encoding DNA to target tissues and has been applied in clinical trials [118, 123, 124].”
BackgroundMethodInfluentialThe genetic basis of congenital anomalies of the kidney and urinary tract
Kagan, M., Pleniceanu, O., & Vivante, A. (2022) · Pediatric Nephrology · doi:10.1007/s00467-021-05420-1 · Cited by 79
“, CRISPR-Cas9 technology) to correct germline mutations [88].”
BackgroundCRISPR Spherical Nucleic Acids
Huang, C., Han, Z., Evangelopoulos, M., & Mirkin, C. A. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c07913 · Cited by 68
Enabling technology and core theory of synthetic biology
Zhang, X., Liu, C., Dai, J., Yuan, Y., Gao, C., Feng, Y. F., Wu, B., Wei, P., You, C., Wang, X., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2214-2 · Cited by 75
“…base editing to treat genetic disorders like sickle cell anemia (Newby et al., 2021), progeria (Koblan et al., 2021), trans-thyretin amyloidosis (Gillmore et al., 2021) or genetic conditions like hypercholesteremia (Verve Therapeutics, 2022.…”
BackgroundTargeted genome editing with a DNA-dependent DNA polymerase and exogenous DNA-containing templates
Liu, B., Dong, X., Zheng, C., Keener, D. G., Chen, Z., Cheng, H., Watts, J. K., Xue, W., & Sontheimer, E. J. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01947-w · Cited by 67
The future of liver transplantation
Feng, S., Roll, G. R., Rouhani, F. J., & Fueyo, A. S. (2024) · Hepatology · doi:10.1097/hep.0000000000000873 · Cited by 77
“[126] Liver-targeted nanoparticles are also being used to “ base edit ” (change a single nucleotide) and thereby inactivate PCSK9 , also leading to substantial ( ≥ 39”
Charge-altering releasable transporters enhance mRNA delivery in vitro and exhibit in vivo tropism
Li, Z., Amaya, L., Pi, R., Wang, S. K., Ranjan, A., Waymouth, R. M., Blish, C. A., Chang, H. Y., & Wender, P. A. (2023) · Nature Communications · doi:10.1038/s41467-023-42672-x · Cited by 75
“Emerging RNA technologies have enabled new and often remarkably effective strategies for therapeutic and prophylactic vaccinations 1 , immunotherapies 2 , and genome editing 3 .”
BackgroundHofstraat, S. R. J., Anbergen, T., Zwolsman, R. C., Deckers, J., van Elsas, Y., Trines, M. M., Versteeg, I., Hoorn, D., Ros, G. W. B., Bartelet, B. M., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-024-01847-3 · Cited by 89
“Furthermore, LNP technology was essential for the COVID-19 messenger RNA (mRNA) vaccines 4,5 , and facilitates in vivo gene editing approaches currently undergoing clinical evaluation 6,7 .”
ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected
Boutin, J., Cappellen, D., Rosier, J., Amintas, S., Dabernat, S., Bedel, A., & Moreau‐Gaudry, F. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0120 · Cited by 68
“26,27 Despite successes and rapid development, several obstacles must be overcome before these strategies can be fully exploited.”
Kumar, R., Le, N., Oviedo, F., Brown, M. E., & Reineke, T. M. (2022) · JACS Au · doi:10.1021/jacsau.1c00467 · Cited by 69
Genetic risk factors have a substantial impact on healthy life years
Jukarainen, S., Kiiskinen, T., Kuitunen, S., Havulinna, A. S., Karjalainen, J. M., Cordioli, M., Rämö, J. T., Mars, N., FinnGen, Samocha, K. E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01957-2 · Cited by 78
Yu, F., Gong, D., Yan, D., Wang, H., Witman, N., Yang, L., Fu, W. E., & Fu, Y. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.05.002 · Cited by 73
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



